EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Genicular Artery Embolization, Radiofrequency Ablation, and Corticosteroid Therapy for Knee Osteoarthritis: A Cost-Effectiveness Analysis Using Randomized Clinical Trial Data

Daniel H Kwak, Hayden L Hofmann, Mikin Patel, Daniel B Heller, Aaron Lyons, Qian Yu, David D Kim, Osman Ahmed

American Journal of Roentgenology · 2024-12 · 223 (6)

DOI: 10.2214/ajr.24.31710 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Roentgenology, 2024-12. Verfasst von Daniel H Kwak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Section of Interventional Radiology, The University of Chicago Medical Center, 5841 S Maryland Ave, Chicago, IL 60637. Hauptthemen laut MEDLINE: Osteoarthritis, Knee, Cost-Benefit Analysis, Radiofrequency Ablation, Adrenal Cortex Hormones. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND. Many patients with knee osteoarthritis (KOA) have symptoms that are refractory to traditional nonsurgical treatments, such as intraarticular corticosteroid (CS) injection, but are not yet eligible are not yet eligible for or decline surgery. Genicular artery embolization (GAE) and radiofrequency ablation (RFA) are emerging adjunctive or alternative minimally invasive treatments. OBJECTIVE. The purpose of this study was to perform a cost-effectiveness analysis (CEA) comparing CS therapy, GAE, and RFA for the treatment of symptomatic KOA using a Markov model based on a de novo network meta-analysis (NMA) of randomized control trials. METHODS. A CEA was conducted to compare GAE and RFA to CS using a Markov cohort state-transition model from a U.S. Medicare payer's perspective over a 4-year time horizon. The model incorporated each treatment's success and attrition rates, costs, and utility benefit. Utility benefit values were derived at short-term (0.5-3 months) and long-term (6-12 months) posttreatment follow-up from an NMA of published randomized controlled trials using an outcome of improved knee pain and/or function. Analyses were conducted at a willingness-to-pay threshold of US$100,000 per quality-adjusted life year (QALY) gained. Sensitivity analyses were performed, including when simulating various cost setting scenarios (i.e., office vs hospital outpatient treatment). RESULTS. RFA showed larger treatment effect than GAE, which was more pronounced at short-term follow-up (standardized mean difference [SMD] for RFA, -1.6688 [95% CI, -2.7806 to -0.5571], p = .003; SMD for GAE, -0.3822 [95% CI, -1.9743 to 1.2100], p = .64) than at long-term follow-up. Across cost setting scenarios, incremental cost-effectiveness ratios relative to CS therapy were US$561-1563 per QALY gained for GAE versus US$76-429 per QALY gained for RFA (not counting scenarios in which RFA was dominated by CS). GAE showed higher cost-effectiveness probability compared with RFA (41.6-54.8% vs 18.4-29.2%, respectively). GAE was more cost-effective than RFA when the GAE clinical success rate and post-GAE utility value exceeded 32.1-51.0% and 0.562-0.617, respectively, and when the GAE quarterly attrition rate was less than 8.8-17.4%. RFA was more cost-effective when baseline pretreatment utility values exceeded 0.695-0.713. Neither GAE costs nor RFA costs were sensitive parameters. CONCLUSION. Across scenarios, GAE was consistently the most likely cost-effective treatment option compared with RFA and CS, although clinical success rates, attrition rates, and utility values impact its cost-effectiveness. CLINICAL IMPACT. GAE is likely to be more cost-effective than RFA or CS for treatment of symptomatic KOA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoarthritis, KneeCost-Benefit AnalysisRadiofrequency AblationAdrenal Cortex HormonesRandomized Controlled Trials as TopicEmbolization, TherapeuticHumansMarkov ChainsFemaleMaleTreatment OutcomeUnited StatesCost-Effectiveness Analysis

Stichwörter der Autor:innen

cost-effectivenessgenicular artery embolizationhealth care economicsinterventional radiologyknee osteoarthritis

Substanzen

Adrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Radiology, Section of Interventional Radiology, The University of Chicago Medical Center, 5841 S Maryland Ave, Chicago, IL 60637.
  • Keck School of Medicine of University of Southern California, Los Angeles, CA.
  • Department of Radiology, Loyola University Medical Center, Maywood, IL.
  • University of Washington School of Medicine, Seattle, WA.
  • Department of Medicine, Section of Hospital Medicine, University of Chicago, Chicago, IL.

Zitieren

APA

Kwak, D. H., Hofmann, H. L., Patel, M., Heller, D. B., Lyons, A., Yu, Q., Kim, D. D., & Ahmed, O. (2024). Genicular Artery Embolization, Radiofrequency Ablation, and Corticosteroid Therapy for Knee Osteoarthritis: A Cost-Effectiveness Analysis Using Randomized Clinical Trial Data. American Journal of Roentgenology, 223(6). https://doi.org/10.2214/ajr.24.31710

Vancouver

Kwak DH, Hofmann HL, Patel M, Heller DB, Lyons A, Yu Q, et al. Genicular Artery Embolization, Radiofrequency Ablation, and Corticosteroid Therapy for Knee Osteoarthritis: A Cost-Effectiveness Analysis Using Randomized Clinical Trial Data. American Journal of Roentgenology. 2024;223(6). doi:10.2214/ajr.24.31710

BibTeX
@article{Kwak2024,
  author = {Kwak, Daniel H and Hofmann, Hayden L and Patel, Mikin and Heller, Daniel B and Lyons, Aaron and Yu, Qian and Kim, David D and Ahmed, Osman},
  title = {Genicular Artery Embolization, Radiofrequency Ablation, and Corticosteroid Therapy for Knee Osteoarthritis: A Cost-Effectiveness Analysis Using Randomized Clinical Trial Data},
  journal = {American Journal of Roentgenology},
  year = {2024},
  volume = {223},
  number = {6},
  doi = {10.2214/ajr.24.31710}
}
Kostenlos starten →